Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 9/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 6/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.59 |
| ▸ | ULK1 | O75385 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12886503 | 0.93 | MAPK10 (0.68) | MAPK10MAPK9PTK2ULK1TTK | |
| SCHEMBL12887661 | 0.88 | MAPK10 (0.60) | MAPK10MAPK9PTK2ULK1TTK | |
| SCHEMBL12886497 | 0.81 | MAPK10 (0.72) | MAPK10MAPK9PTK2ULK1TTK | |
| SCHEMBL12887007 | 0.81 | MAPK10 (0.57) | MAPK10MAPK9PTK2ULK1TTK | |
| SCHEMBL12886500 | 0.80 | MAPK10 (0.60) | MAPK10MAPK9PTK2ULK1ALK | |
| SCHEMBL15964228 | 0.80 | MAPK10 (0.85) | MAPK10MAPK9PTK2ULK1ALK | |
| SCHEMBL12887709 | 0.79 | MAPK10 (0.58) | MAPK10MAPK9PTK2ULK1TTK | |
| SCHEMBL18559526 | 0.78 | MAPK10 (0.76) | MAPK10MAPK9PTK2ULK1TTK | |
| SCHEMBL12886660 | 0.77 | ULK1 (0.76) | MAPK10MAPK9PTK2ULK1TTK | |
| SCHEMBL1230803 | 0.76 | PTK2 (0.53) | MAPK10MAPK9PTK2ULK1TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580439-B2 | Inhibitors of focal adhesion kinase | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-28 | — | — | US | disclosed |
| US-20130281443-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-10-24 | — | — | US | disclosed |
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046121-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK10 590/4885MAPK9 239/4885PTK2 1/4885 |
| US-20130281443-A1 | INHIBITORS OF FOCAL ADHESION KINASE | PTK2, CABLES1, TNK2 | MAPK10 590/4885MAPK9 239/4885PTK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.